These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 9777116)

  • 1. Emergency coronary artery bypass grafting (CABG) after failed coronary artery intervention--caution regarding the combined use of aspirin, ticlopidine and abciximab.
    Alvarez JM; Harper RW; Peverill RE
    Aust N Z J Med; 1998 Aug; 28(4):463-4. PubMed ID: 9777116
    [No Abstract]   [Full Text] [Related]  

  • 2. Glycoprotein IIb/IIIa inhibitors, surgery and bleeding.
    Aylward P
    Aust N Z J Med; 1998 Oct; 28(5):583-4. PubMed ID: 9847944
    [No Abstract]   [Full Text] [Related]  

  • 3. How should I treat subacute stent thrombosis in the context of brain haemorrhage with abciximab?
    Martin-Yuste V; Alvarez-Contreras L; Sabaté M; Kelbaek H; Saunamäki K; Jørgensen E; Kocka V
    EuroIntervention; 2015 Feb; 10(10):e1-6. PubMed ID: 25701264
    [No Abstract]   [Full Text] [Related]  

  • 4. Incidence of thrombocytopenia following coronary stent placement using abciximab plus clopidogrel or ticlopidine.
    Dillon WC; Eckert GJ; Dillon JC; Ritchie ME
    Catheter Cardiovasc Interv; 2000 Aug; 50(4):426-30. PubMed ID: 10931614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emergency coronary bypass grafting for failed percutaneous coronary artery stenting: increased costs and platelet transfusion requirements after the use of abciximab.
    Alvarez JM
    J Thorac Cardiovasc Surg; 1998 Feb; 115(2):472-3. PubMed ID: 9475547
    [No Abstract]   [Full Text] [Related]  

  • 6. Abciximab in the treatment of acute myocardial infarction eligible for primary percutaneous transluminal coronary angioplasty. Results of the Glycoprotein Receptor Antagonist Patency Evaluation (GRAPE) pilot study.
    van den Merkhof LF; Zijlstra F; Olsson H; Grip L; Veen G; Bär FW; van den Brand MJ; Simoons ML; Verheugt FW
    J Am Coll Cardiol; 1999 May; 33(6):1528-32. PubMed ID: 10334418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emergent operation for percutaneous coronary rupture after abciximab administration.
    Roberts CS; Bocanegra NR
    Ann Thorac Surg; 2001 Jun; 71(6):2024-6. PubMed ID: 11426792
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long term efficacy of abciximab bolus-only compared to abciximab bolus and infusion after transradial coronary stenting.
    Bagur R; Bertrand OF; Rodés-Cabau J; Larose E; Rinfret S; Nguyen CM; Noel B; Larochellière RD; Poirier P; Costerousse O; Roy L
    Catheter Cardiovasc Interv; 2009 Dec; 74(7):1010-6. PubMed ID: 19753635
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute stent thrombosis associated with heparin-induced thrombocytopenia and abciximab-induced profound thrombocytopenia.
    Dasari TW; Pappy R; Hennebry TA
    J Invasive Cardiol; 2011 Feb; 23(2):E5-8. PubMed ID: 21297217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized two-by-two comparison of high-dose bolus tirofiban versus abciximab and unfractionated heparin versus bivalirudin during percutaneous coronary revascularization and stent placement: the tirofiban evaluation of novel dosing versus abciximab with clopidogrel and inhibition of thrombin (TENACITY) study trial.
    Moliterno DJ;
    Catheter Cardiovasc Interv; 2011 Jun; 77(7):1001-9. PubMed ID: 21598351
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of ticlopidine for only 2 weeks after successful intracoronary stent placement.
    Berger PB; Bell MR; Hasdai D; Grill DE; Melby S; Holmes DR
    Circulation; 1999 Jan; 99(2):248-53. PubMed ID: 9892591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade.
    EPISTENT Investigators
    Lancet; 1998 Jul; 352(9122):87-92. PubMed ID: 9672272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of a high on-clopidogrel treatment platelet reactivity in bivalirudin versus abciximab treated non-ST-segment elevation myocardial infarction patients. ISAR-REACT 4 (Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment-4) platelet substudy.
    Sibbing D; Bernlochner I; Schulz S; Massberg S; Schömig A; Mehilli J; Kastrati A
    J Am Coll Cardiol; 2012 Jul; 60(5):369-77. PubMed ID: 22682553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Routine platelet transfusion in patients undergoing emergency coronary bypass surgery after receiving abciximab.
    Juergens CP; Yeung AC; Oesterle SN
    Am J Cardiol; 1997 Jul; 80(1):74-5. PubMed ID: 9205024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Coronary stenting and use of abciximab.
    Alvarez JM
    Lancet; 1998 Oct; 352(9136):1311-2. PubMed ID: 9788484
    [No Abstract]   [Full Text] [Related]  

  • 16. A risk-benefit assessment of abciximab in angioplasty.
    Kleiman NS
    Drug Saf; 1999 Jan; 20(1):43-57. PubMed ID: 9935276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glycoprotein IIb/IIIa receptor inhibition with abciximab during percutaneous coronary interventions increases the risk of bleeding in patients with impaired renal function.
    Pinkau T; Ndrepepa G; Kastrati A; Mann JF; Schulz S; Mehilli J; Schömig A
    Cardiology; 2008; 111(4):247-53. PubMed ID: 18434733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence of bleeding complications associated with abciximab use in conjunction with thrombolytic therapy in patients requiring percutaneous transluminal coronary angioplasty.
    Sundlof DW; Rerkpattanapitat P; Wongpraparut N; Pathi P; Kotler MN; Jacobs LE; Ledley GS; Yazdanfar S
    Am J Cardiol; 1999 Jun; 83(11):1569-71, A7. PubMed ID: 10363875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
    Kastrati A; Mehilli J; Schühlen H; Dirschinger J; Dotzer F; ten Berg JM; Neumann FJ; Bollwein H; Volmer C; Gawaz M; Berger PB; Schömig A;
    N Engl J Med; 2004 Jan; 350(3):232-8. PubMed ID: 14724302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial.
    Tcheng JE; Kandzari DE; Grines CL; Cox DA; Effron MB; Garcia E; Griffin JJ; Guagliumi G; Stuckey T; Turco M; Fahy M; Lansky AJ; Mehran R; Stone GW;
    Circulation; 2003 Sep; 108(11):1316-23. PubMed ID: 12939213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.